Novel effects with polyethylene glycol modified pharmaceuticals
- PMID: 12173408
- DOI: 10.1016/s0305-7372(02)80002-0
Novel effects with polyethylene glycol modified pharmaceuticals
Abstract
Proteins undergo extensive hydrolysis in the gastrointestinal tract and have short circulating half-lives in the blood. For optimal clinical efficacy, therefore, they must be given by daily injections. Attaching a polyethylene glycol (PEG) moiety (pegylation) improves the pharmacokinetic and pharmacodynamic profiles of proteins. Pegfilgrastim (pegylated filgrastim) has a longer half-life than unmodified filgrastim and, when administered as a single dose, has been shown to be at least as efficacious as daily filgrastim. Because of its reduced renal clearance, the elimination of pegfilgrastim is predominantly neutrophil-mediated, so its clearance is self-regulated. In addition, pegfilgrastim can be administered at a fixed dose instead of in weight-based doses. For these reasons, pegfilgrastim can potentially increase patient adherence and acceptance of treatment, thus having a beneficial effect on their quality of life. Furthermore, treatment is likely to cost less because of the reduced need for medical interventions. Similarly, pegylated liposomal doxorubicin has a longer half-life than unmodified doxorubicin and has been shown, because of its reduced reticuloendothelial system clearance, to produce higher concentrations of doxorubicin in tumours and to have greater clinical efficacy than doxorubicin in the treatment of some solid tumours. Pegylated liposomal doxorubicin is also associated with less myelosuppression and febrile neutropenia.
Similar articles
-
Pegylation: engineering improved pharmaceuticals for enhanced therapy.Cancer Treat Rev. 2002 Apr;28 Suppl A:13-6. doi: 10.1016/s0305-7372(02)80004-4. Cancer Treat Rev. 2002. PMID: 12173407 Review.
-
Clinical uses of pegylated pharmaceuticals in oncology.Cancer Treat Rev. 2002 Apr;28 Suppl A:7-11. doi: 10.1016/s0305-7372(02)80003-2. Cancer Treat Rev. 2002. PMID: 12173409 Review.
-
Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients.Anticancer Drugs. 2003 Apr;14(4):259-64. doi: 10.1097/00001813-200304000-00002. Anticancer Drugs. 2003. PMID: 12679729 Review.
-
Pharmacokinetics of pegfilgrastim.Pharmacotherapy. 2003 Aug;23(8 Pt 2):9S-14S. doi: 10.1592/phco.23.9.9s.32888. Pharmacotherapy. 2003. PMID: 12921217 Review.
-
Pharmacokinetics and pharmacodynamics of pegfilgrastim.Clin Pharmacokinet. 2011 May;50(5):295-306. doi: 10.2165/11586040-000000000-00000. Clin Pharmacokinet. 2011. PMID: 21456630 Review.
Cited by
-
'Click' synthesis of dextran macrostructures for combinatorial-designed self-assembled nanoparticles encapsulating diverse anticancer therapeutics.Bioorg Med Chem. 2011 Nov 1;19(21):6167-73. doi: 10.1016/j.bmc.2011.09.024. Epub 2011 Sep 17. Bioorg Med Chem. 2011. PMID: 21978947 Free PMC article.
-
Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers.Pharmaceutics. 2014 Jun 20;6(2):333-53. doi: 10.3390/pharmaceutics6020333. Pharmaceutics. 2014. PMID: 24955820 Free PMC article.
-
MRI contrast agent for targeting glioma: interleukin-13 labeled liposome encapsulating gadolinium-DTPA.Neuro Oncol. 2016 May;18(5):691-9. doi: 10.1093/neuonc/nov263. Epub 2015 Oct 31. Neuro Oncol. 2016. PMID: 26519740 Free PMC article.
-
Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization.PLoS One. 2014 Nov 7;9(11):e112448. doi: 10.1371/journal.pone.0112448. eCollection 2014. PLoS One. 2014. PMID: 25380141 Free PMC article.
-
New insight into strategies used to develop long-acting G-CSF biologics for neutropenia therapy.Front Oncol. 2023 Jan 5;12:1026377. doi: 10.3389/fonc.2022.1026377. eCollection 2022. Front Oncol. 2023. PMID: 36686781 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources